Skip to main content

Malibu Boats, Inc. Announces First Quarter Fiscal 2026 Results

LOUDON, Tenn., Oct. 30, 2025 (GLOBE NEWSWIRE) — Malibu Boats, Inc. (Nasdaq: MBUU) today announced its financial results for the first quarter ended September 30, 2025. First Quarter Fiscal 2026 Highlights Compared to First Quarter Fiscal 2025:Net sales increased 13.5% to $194.7 million Unit volume increased 10.3% to 1,129 units Gross profit decreased 1.0% to $27.9 million GAAP net loss decreased 86.2% from a net loss of $5.1 million to a net loss of $0.7 million GAAP net loss available to Class A Common Stock per share (diluted) decreased 84.0% from a net loss of $0.25 per share to a net loss of $0.04 per share Adjusted EBITDA increased 19.1% to $11.8 million Adjusted net income per share increased 114.3% to $0.15 per share on a basic weighted-average share count of 19.3 million shares of Class A Common Stock“We delivered...

Continue reading

LKQ Corporation Announces Results for Third Quarter 2025

Simplified Portfolio with Successful Closing on Sale of Self Service Segment Returned $118 Million of Capital to Shareholders; $40 Million of Share Repurchases and $78 Million in Cash Dividends Raised Midpoint and Narrowed Range for Full Year 2025 EPS Outlook Following Sale of Self Service ANTIOCH, Tenn., Oct. 30, 2025 (GLOBE NEWSWIRE) — LKQ Corporation (Nasdaq: LKQ) today reported third quarter 2025 financial results and updates outlook for 2025 following the sale of the Company’s Self Service segment. For the periods presented, the Company’s Self Service segment, which was sold on September 30, 2025, has been classified as discontinued operations. Unless otherwise noted, the discussion in this earnings release focuses on continuing operations and excludes discontinued operations for all periods presented. Third Quarter...

Continue reading

HII Reports Third Quarter 2025 Results

NEWPORT NEWS, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) — HII (NYSE: HII) today reported results for the third quarter of fiscal 2025. HighlightsThird quarter revenues were a record $3.2 billion Third quarter net earnings were $145 million or $3.68 diluted earnings per share Completed builder’s sea trials for guided missile destroyer Ted Stevens (DDG 128) Completed initial sea trials of Virginia-Class Submarine Massachusetts (SSN 798) in early OctoberThird Quarter ResultsThird quarter 2025 revenues of $3.2 billion were up 16.1% from the third quarter of 2024, driven by growth at Newport News Shipbuilding, Ingalls Shipbuilding and Mission Technologies. Operating income in the third quarter of 2025 was $161 million and operating margin was 5.0%, compared to $82 million and 3.0%, respectively, in the third quarter of 2024. Segment...

Continue reading

Iceland Seafood International hf: Q3 2025 results and investors presentation

Iceland Seafood will publish its Interim Financial Statement for Q3 2025 after closing of markets on November 13th 2025. This represents a change from the previously scheduled date of November 19th, moving the publication forward by six days. Iceland Seafood will pause hosting a meeting for investors and market participants for Q1 and Q3 until further notice. However, the company will host a meeting for investors and market participants for Q2 (half-year results) and Q4 (full-year results), where management will present and discuss the results.  Dates for those meetings can be found on the company website  www.icelandseafood.com/investors/shareholders/

Continue reading

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product sales Received 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary IC-MPGN Reported EMPAVELI U.S. net product revenue of $27 million, reflecting strong early launch in C3G and primary IC-MPGN and continued high patient compliance in PNH SYFOVRE® (pegcetacoplan injection) total injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $151 million Cash and cash equivalents of $479 million as of September 30, 2025; existing cash expected to be sufficient to fund business to sustainable profitability Management to host conference call today at 8:30 a.m. ETWALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced...

Continue reading

Wabash Announces Third Quarter 2025 Results

Quarterly revenue of $382 million – Softer than expected demand, particularly in our Truck Body business, led to revenue coming in below our guidance range. Parts & Services generated positive revenue growth sequentially and year-over-year. GAAP operating income of $58 million or Non-GAAP adjusted operating loss of $24 million; Excludes impact of $81 million gain related to the settlement of the Missouri legal verdict. Quarterly GAAP EPS of $0.97 or Non-GAAP adjusted EPS of $(0.51). Missing Expectations due to revenue miss and operational inefficiencies associated with lower than expected volumes. Total backlog of $829 million ending Q3; Market environment continues to be challenging as economic concerns and uncertainty remain. 2025 revenue outlook reduced to $1.5B, Non-GAAP adjusted EPS outlook reduced to $(2.00), excluding...

Continue reading

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

$12.9 million in third quarter PYRUKYND® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026 RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026 Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results expected in early 2026 $1.3 billion dollars in cash, cash equivalents and marketable securities as of September 30, 2025CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended...

Continue reading

Donegal Group Inc. Announces Third Quarter and First Nine Months of 2025 Results

MARIETTA, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) — Donegal Group Inc. (NASDAQ: DGICA) and (NASDAQ: DGICB) today reported its financial results for the third quarter and first nine months of 2025. Significant Items for third quarter of 2025 (all comparisons to third quarter of 2024):Net premiums earned decreased 3.4% to $229.8 million Combined ratio of 95.9%, compared to 96.4% Net income of $20.1 million, or 55 cents per diluted Class A share, compared to $16.8 million, or 51 cents per diluted Class A share Net income included after-tax net investment gains of $1.0 million, or 3 cents per diluted Class A share, compared to $1.5 million, or 5 cents per diluted Class A share Annualized return on average equity of 13.0%, compared to 13.4% Book value per share of $17.14 at September 30, 2025, compared to $15.22Financial Summary                         Three...

Continue reading

Kimco Realty® Announces Third Quarter 2025 Results

– Achieves Record Leased-to-Economic Occupancy Spread –– New High in Small Shop Occupancy –– 4% Increase to Cash Dividend on Common Shares –– Raises 2025 Outlook Range – JERICHO, N.Y., Oct. 30, 2025 (GLOBE NEWSWIRE) — Kimco Realty® (NYSE: KIM), a real estate investment trust (REIT) and leading owner and operator of high-quality, open-air, grocery-anchored shopping centers and mixed-use properties in the United States, today reported results for the third quarter ended September 30, 2025. For the three months ended September 30, 2025 and 2024, Net income available to the company’s common shareholders (“Net income”) per diluted share was $0.19 for both periods. HighlightsProduced Funds From Operations(1) (“FFO”) of $0.44 per diluted share. Grew pro-rata portfolio occupancy to 95.7%, up 30 basis points sequentially. Reached an...

Continue reading

XPO Reports Third Quarter 2025 Results

GREENWICH, Conn., Oct. 30, 2025 (GLOBE NEWSWIRE) — XPO (NYSE: XPO) today announced its financial results for the third quarter 2025. The company reported diluted earnings per share of $0.68, compared with $0.79 for the same period in 2024, and adjusted diluted earnings per share of $1.07, compared with $1.02 for the same period in 2024.Third Quarter 2025 Summary Results                                     Three Months Ended September 30,    Revenue   Operating Income (Loss)(1)(in millions)     2025     2024   Change %     2025       2024     Change %North American Less-Than-Truckload Segment   $ 1,255   $ 1,251   0.3 %   $ 208     $ 188     10.6 %European Transportation Segment     857     803   6.7 %     (2 )     6     NMCorporate     –     –   0.0 %     (42 )     (18 )   133.3 %Total   $ 2,111   $ 2,053   2.8 %   $ 164     $ 176     -6.8 %                                     Adjusted...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.